SpringWorks Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
SpringWorks Therapeutics has a total shareholder equity of $567.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $656.8M and $89.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$436.58m |
| Equity | US$567.44m |
| Total liabilities | US$89.39m |
| Total assets | US$656.83m |
Recent financial health updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06Recent updates
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15SpringWorks shows durable effect for neurofibroma therapy with long-term data
Jun 15SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma
Jun 07We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow
May 31SpringWorks Therapeutics EPS misses by $0.11
May 06SpringWorks Therapeutics announces C-level promotions
Dec 15SpringWorks Therapeutics EPS misses by $0.02
Nov 12Financial Position Analysis
Short Term Liabilities: SWTX's short term assets ($471.8M) exceed its short term liabilities ($68.9M).
Long Term Liabilities: SWTX's short term assets ($471.8M) exceed its long term liabilities ($20.5M).
Debt to Equity History and Analysis
Debt Level: SWTX is debt free.
Reducing Debt: SWTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SWTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SWTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 41.8% each year.